YuWen Hwang
Research Subjects
YuWen Hwang has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Ganesh Raghu
Division of Pulmonary, Critical Care and Sleep Medicine, Center for Interstitial Lung Diseases, Department of Medicine, University of Washington
1 shared publication - Gian Luca Araldi
Avanti Biosciences, Inc., 3210 Merryfield Row, San Diego, CA 92121, USA
1 shared publication
Latest Publications
- Open Access
- 4 October 2024
- Published by MDPI AG in Preprints.org
Development and Evaluation of ABI-171, a New Fluoro Catechin Derivative, for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
The persistent challenge of IPF, characterized by disease progression and high mortality, underscores the urgent need for innovative therapeutic strategies. We have developed a novel small molecule – catechin derivative ABI-171 – selectively targeting DYRK1A and PIM1 kinases, crucial in the pathogenesis of fibrotic processes. We employed the Bleomycin-induced (intratracheal) mouse model of pulmonary fibrosis (PF) to evaluate the therapeutic efficacy of ABI-171. Mice with induced PF were treated QD with ABI-171 either prophylactically or therapeutically using oral and intranasal routes. Pirfenidone (100mg/kg, TID) and Epigallocatechin gallate (EGCG, 100 mg/kg, QD), a natural catechin currently in a Phase 1 clinical trial, were used as reference compounds. ABI-171, administered prophylactically, led to a significant reduction in hydroxyproline levels and fibrotic tissue formation compared to the control group. Treatment with ABI-171 improved body weight, indicating mitigation of disease-related weight loss. Additionally, ABI-171 demonstrated anti-inflammatory activity, reducing lymphocyte and neutrophil infiltration. In the therapeutic setting, ABI-171, administered 7 days post-induction, reduced mortality rates (P = 0.04) compared with the bleomycin and EGCG control groups. ABI-171 also ameliorated the severity of lung injuries assessed by improved Masson’s trichrome scores when administered both orally and intranasally. ABI-171 significantly decreases bleomycin-induced PF and improves survival in mice, showcasing promising therapeutic potential beyond current medications like Pirfenidone and EGCG for patients with IPF. Based on these results, further studies with ABI-171 are ongoing in preclinical studies.
- 4 October 2024
- Published by MDPI AG in Preprints.org
Open AccessDevelopment and Evaluation of ABI-171, a New Fluoro Catechin Derivative, for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
The persistent challenge of IPF, characterized by disease progression and high mortality, underscores the urgent need for innovative therapeutic strategies. We have developed a novel small molecule – catechin derivative ABI-171 – selectively targeting DYRK1A and PIM1 kinases, crucial in the pathogenesis of fibrotic processes. We employed the Bleomycin-induced (intratracheal) mouse model of pulmonary fibrosis (PF) to evaluate the therapeutic efficacy of ABI-171. Mice with induced PF were treated QD with ABI-171 either prophylactically or therapeutically using oral and intranasal routes. Pirfenidone (100mg/kg, TID) and Epigallocatechin gallate (EGCG, 100 mg/kg, QD), a natural catechin currently in a Phase 1 clinical trial, were used as reference compounds. ABI-171, administered prophylactically, led to a significant reduction in hydroxyproline levels and fibrotic tissue formation compared to the control group. Treatment with ABI-171 improved body weight, indicating mitigation of disease-related weight loss. Additionally, ABI-171 demonstrated anti-inflammatory activity, reducing lymphocyte and neutrophil infiltration. In the therapeutic setting, ABI-171, administered 7 days post-induction, reduced mortality rates (P = 0.04) compared with the bleomycin and EGCG control groups. ABI-171 also ameliorated the severity of lung injuries assessed by improved Masson’s trichrome scores when administered both orally and intranasally. ABI-171 significantly decreases bleomycin-induced PF and improves survival in mice, showcasing promising therapeutic potential beyond current medications like Pirfenidone and EGCG for patients with IPF. Based on these results, further studies with ABI-171 are ongoing in preclinical studies.